Sarepta Therapeutics Inc
Change company Symbol lookup
Select an option...
SRPT Sarepta Therapeutics Inc
CASY Caseys General Stores Inc
AEO American Eagle Outfitters Inc
WBS Webster Financial Corp
MYI BlackRock MuniYield Quality Fund III, Inc.
RUN Sunrun Inc
SEIL Zhongke Biotech Agriculture (USA) Inc
V Visa Inc
UAA Under Armour Inc
WWFS Patty S Olney
Go

Health Care : Biotechnology | Small Cap GrowthCompany profile

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Closing Price
$51.94
Day's Change
1.22 (2.41%)
Bid
--
Ask
--
B/A Size
--
Day's High
52.11
Day's Low
50.38
Volume
(Average)
Volume:
1,669,506
10-day average volume:
1,532,802
1,669,506
  • Prev Close
    50.72
  • Today's Open
    50.80
  • Day's Range
    50.38-52.11
  • Avg Vol (10-day)
    1.5M
  • Last (time)
    3:59p ET 10/20/17
  • Last (size)
    25
  • 52-Wk Range
    26.26 - 52.67
    LowHigh
  • (02/13/17 - 10/18/17)
    1.39%
  • 57.0%
  • Market Cap
    3.3B
  • Shares Outstanding
    64.3M
  • -2.44
  • --
  • No dividend
  • Ex-dividend
    No dividend
  • 1.3
  • 64.96
  • (% of float 09/29/17)
    15.04

Latest News

October 16, 2017
12:30 pm ET
Globe Newswire
October 09, 2017
12:30 pm ET
MarketWatch
October 09, 2017
12:22 pm ET
MarketWatch
October 02, 2017
2:25 pm ET
MarketWatch
October 02, 2017
2:06 pm ET
MarketWatch
October 02, 2017
1:28 pm ET
MarketWatch
September 29, 2017
10:30 pm ET
Globe Newswire
September 29, 2017
3:36 pm ET
MarketWatch
September 29, 2017
3:28 pm ET
MarketWatch
September 28, 2017
12:30 pm ET
Globe Newswire
September 25, 2017
12:30 pm ET
Globe Newswire
September 14, 2017
10:50 am ET
PR Newswire
September 07, 2017
10:55 am ET
MarketWatch
September 06, 2017
5:45 pm ET
MarketWatch
September 06, 2017
3:21 pm ET
MarketWatch
September 06, 2017
12:30 pm ET
Globe Newswire
September 06, 2017
11:05 am ET
MarketWatch
September 06, 2017
11:02 am ET
MarketWatch
September 06, 2017
11:00 am ET
Globe Newswire
September 05, 2017
2:00 pm ET
Globe Newswire
August 31, 2017
10:30 pm ET
Globe Newswire
August 24, 2017
9:30 am ET
Globe Newswire
August 07, 2017
10:10 am ET
PR Newswire
July 31, 2017
10:30 pm ET
Globe Newswire
July 27, 2017
12:30 pm ET
Globe Newswire
July 25, 2017
12:00 am ET
Globe Newswire
July 24, 2017
11:00 am ET
Globe Newswire
July 19, 2017
9:37 pm ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2017 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by SunGard.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2017. All rights reserved.